Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed azathioprine or rituximab in pediatric MOG antibody-associated demyelinating disease
2022-002385-32Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azathioprine, rituximab, methylprednisolone and prednisolone in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Annualized relapse rate at 24 months. Started Jul 2022; status: active.
02
Drugs
azathioprinerituximabmethylprednisoloneprednisolone
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2022-002385-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002385-32.